微RNA在慢性淋巴细胞白血病中的研究进展  

Progress of microRNAs in chronic lymphocytic leukemia

作　　者：谢汶晃 查显丰[1] 温旺荣[1] Xie Wenhuang Zha Xianfeng Wen Wangrong(Department of Clinical Laboratory, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China)

机构地区：[1]暨南大学附属第一医院临床检验中心,广州510632

出　　处：《白血病．淋巴瘤》2017年第7期445-448,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81400109）

摘　　要：微RNA（miRNA）是一类长约19~25 nt的单链非编码小RNA,在各种生物体细胞的生长、分化、增殖和凋亡、脂肪代谢等生理进程中发挥重要作用.大量研究表明,miRNA失调与慢性淋巴细胞白血病（CLL）的进展、预后和耐药相关.miR-15a/16-1、miR-34b/c、miR-181b、miR-29、miR-3676、miR-17/92以及miR-155家族成员调节重要基因的表达,是CLL中最易发生失调的miRNA.为了进一步阐明CLL发生发展的分子机制,文章综述了相关miRNA的调控网络以及同其他调控因子的整合.MicroRNAs （miRNAs）, with 19-25 nucleotides in length, are small non-coding single-stranded RNAs and play an important role in a variety of organisms cell growth, differentiation, proliferation and apoptosis, fat metabolism and other physiological processes. Numerous studies have shown that the deregulation of miRNAs was associated with progression, prognosis and drug resistance of chronic lymphocytic leukemia （CLL）. MiR-15a/16-1 cluster, miRs-34b/c , miR-181b, miR-29, miR-3676, miR-17/92 and miR-155 family members were the most common deregulated miRNAs in CLL, which could regulate important gene expressions. To further clarify molecular mechanism of occurrence and development of CLL, this review focuses on recent advances on the regulatory networks of related miRNAs as well as the integration with other regulators.

关 键 词：白血病 淋巴细胞 慢性 

分 类 号：R733.72[医药卫生—肿瘤]